Clinical Trial Update: Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical study evaluating Rituximab for idiopathic membranous nephropathy with nephrotic syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy
• Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Shoichi Maruyama MD PhD | Conditions: Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic | Phase 3 | Status: RECRUITING